Routine integration of PBS through advanced neuroimaging, biomarkers (amyloid and tau PET imaging, cerebrospinal fluid markers), and digital health records could enable clinicians to identify high-risk patients warranting intensive monitoring, personalized care planning, and early intervention before irreversible vascular-neurodegenerative cascade initiation. The gene discussed is MAPT; the disease is amyloidosis.